Table 3 Cardiac characteristics at enrollment in symptomatic patients with a predominantly cardiac or mixed phenotype according to genotype category
ATTRwt amyloidosis (n = 1142) | Cardiac mutations (n = 307) | Other mutations (n = 718) | |
|---|---|---|---|
Heart failure, n (%) | 1012 (88.6) | 283 (92.2) | 449 (62.5) |
NYHA functional classa, n (%) | |||
I | 107 (10.5) | 27 (9.5) | 78 (17.4) |
II | 612 (59.8) | 140 (49.3) | 220 (49.1) |
III | 278 (27.2) | 102 (35.9) | 133 (29.7) |
IV | 26 (2.5) | 15 (5.3) | 17 (3.8) |
Abnormal ECG, n (%) | 947 (82.9) | 218 (71.0) | 415 (57.8) |
Atrial fibrillation/flutter, n (%) | 420 (36.8) | 56 (18.2) | 53 (7.4) |
Pacemaker implanted, n (%) | 179 (15.7) | 26 (8.5) | 33 (4.6) |
ICD implanted, n (%) | 59 (5.2) | 16 (5.2) | 12 (1.7) |
NT-proBNP (pg/mL), n | 775 | 127 | 253 |
Median (10th, 90th percentile) | 2573.0 (731.0, 9041.0) | 2648.0 (664.0, 8889.0) | 1557.0 (213.0, 8633.0) |
Troponin I (ng/mL), n | 133 | 57 | 58 |
Median (10th, 90th percentile) | 0.1 (0.0, 0.3) | 0.1 (0.0, 0.5) | 0.1 (0.0, 0.6) |
Troponin T (ng/mL), n | 626 | 86 | 215 |
Median (10th, 90th percentile) | 0.1 (0.0, 0.2) | 0.1 (0.0, 0.3) | 0.0 (0.0, 0.1) |